ABSTRACT

Background: This study estimated the economic and organisational impact of using subcutaneous injection (SC) formulations of two monoclonal antibodies (rituximab and trastuzumab) in patients with non-Hodgkin's lymphoma (NHL) and HER2 + breast cancer (BC).

Methods: The database of the Unit of Oncology and Haematology of the IRST of Meldola was used. The analysis was structured as follows: i) measurement of the volume of Day-Hospital activity; ii) identification of activities and time to complete the administration; iii) estimate the mean cost of an SC or IV (intravenous infusion); iv) estimate the impact of SC formulations on the volumes of activities provided; v) estimate the social impact of SC or IV formulations.

Results: The use of an SC formulation was associated a significant reduction in the time that the patient takes to complete the administration (trastuzumab -1 hr 18 min; rituximab -2 hr 24 min) and in consumption of healthcare resources and related costs for trastuzumab (IV: € 1781; SC: € 1701) and rituximab (IV: € 2116; SC: € 1941).

Conclusion: The adoption of the SC formulation for rituximab and trastuzumab can generate a greater value for both the national healthcare system and the patient compared to an IV formulation.

摘要

背景：本研究评估了在非霍奇金淋巴瘤 (NHL) 和 HER2 + 乳腺癌 (BC) 患者中使用两种单克隆抗体（利妥昔单抗和曲妥珠单抗）皮下注射 (SC) 制剂的经济和组织影响。

方法： 使用Meldola IRST肿瘤和血液科的数据库。分析的结构如下： i) 日间医院活动量的测量；ii) 确定活动和完成管理的时间；iii) 估计 SC 或 IV（静脉输注）的平均成本；iv) 估计 SC 配方对所提供活动量的影响；v) 估计 SC 或 IV 制剂的社会影响。

结果：使用 SC 制剂显着减少患者完成给药所需的时间（曲妥珠单抗 -1 小时 18 分钟；利妥昔单抗 -2 小时 24 分钟）以及医疗资源的消耗和曲妥珠单抗的相关成本（IV：1781 欧元；SC：1701 欧元）和利妥昔单抗（IV：2116 欧元；SC：1941 欧元）。

结论：与静脉注射制剂相比，利妥昔单抗和曲妥珠单抗采用皮下注射制剂可为国家医疗保健系统和患者创造更大的价值。